Initial Fluad investigations find no manufacturing defectPreliminary investigations have found no manufacturing defect in the influenza vaccine Fluad, which has been linked to the deaths of 13 older people in Italy.…
Medicines regulator amends conflict of interest rules to ensure suitability of experts The European Medicines Agency has amended its policy on handling declarations of interest to ensure pharmaceutical experts are not unduly excluded.…
EllaOne to be available without prescriptionEllaOne (ulipristal acetate), an emergency contraceptive, is to be made available without a prescription from community pharmacies throughout the European Union.…
Pipeline November 2014 The latest approvals and positive opinions from the European Medicines Agency.…
Immune checkpoint inhibitors bring new hope to cancer patients PD-1 and PD-L1 inhibitors induce a higher response rate across a wider range of tumours than other immunotherapies.…
Forces driving the evolution of biologics into biosimilars and biobetters As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…
European Medicines Agency head steps down after “procedural error” Guido Rasi, the executive director of the European Medicines Agency (EMA), has been forced to step down after a “procedural error” in the process that appointed him to the position.…
Fatal case of progressive multifocal leukoencephalopathy linked to TecfideraA fatal case of progressive multifocal leukoencephalopathy has been reported for the first time in a patient receiving dimethyl fumarate (Tecfidera).…
Strategies to reduce the use of antibiotics in animals New drugs that could eventually replace or reduce the use of antibiotics in animals are in development to help slow the rise of antibiotic resistance.…
Green light for first treatment to target ovarian cancer with BRCA mutation The European Medicines Agency has recommended that Lynparza (olaparib) be approved to combat a type of ovarian cancer for which there are limited treatment options.…